Hancock Whitney’s HCA Healthcare HCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.02M | Sell |
2,621
-1,728
| -40% | -$731K | 0.02% | 439 |
|
|
2026
Q1 | $1.9M | Sell |
4,349
-80
| -2% | -$40.3K | 0.03% | 319 |
|
|
2025
Q4 | $2.07M | Sell |
4,429
-18
| -0.4% | -$8.36K | 0.04% | 290 |
|
|
2025
Q3 | $1.9M | Sell |
4,447
-1,623
| -27% | -$629K | 0.03% | 313 |
|
|
2025
Q2 | $2.33M | Buy |
6,070
+569
| +10% | +$205K | 0.04% | 267 |
|
|
2025
Q1 | $1.9M | Buy |
5,501
+371
| +7% | +$119K | 0.06% | 214 |
|
|
2024
Q4 | $1.54M | Buy |
5,130
+1,019
| +25% | +$356K | 0.05% | 248 |
|
|
2024
Q3 | $1.67M | Buy |
4,111
+205
| +5% | +$75.1K | 0.05% | 226 |
|
|
2024
Q2 | $1.25M | Sell |
3,906
-76
| -2% | -$24.7K | 0.04% | 263 |
|
|
2024
Q1 | $1.33M | Buy |
3,982
+215
| +6% | +$65.7K | 0.05% | 259 |
|
|
2023
Q4 | $1.02M | Sell |
3,767
-131
| -3% | -$32.4K | 0.04% | 309 |
|
|
2023
Q3 | $959K | Buy |
3,898
+220
| +6% | +$60.2K | 0.04% | 308 |
|
|
2023
Q2 | $1.12M | Buy |
3,678
+643
| +21% | +$179K | 0.04% | 288 |
|
|
2023
Q1 | $800K | Buy |
3,035
+1,001
| +49% | +$254K | 0.03% | 337 |
|
|
2022
Q4 | $488K | Sell |
2,034
-117
| -5% | -$26.2K | 0.02% | 433 |
|
|
2022
Q3 | $395K | Sell |
2,151
-566
| -21% | -$113K | 0.02% | 461 |
|
|
2022
Q2 | $457K | Buy |
2,717
+268
| +11% | +$57.6K | 0.02% | 440 |
|
|
2022
Q1 | $614K | Sell |
2,449
-59
| -2% | -$14.8K | 0.02% | 415 |
|
|
2021
Q4 | $644K | Buy |
2,508
+61
| +2% | +$14.9K | 0.02% | 426 |
|
|
2021
Q3 | $594K | Buy |
2,447
+16
| +0.7% | +$3.91K | 0.02% | 426 |
|
|
2021
Q2 | $503K | Sell |
2,431
-55
| -2% | -$11.2K | 0.02% | 547 |
|
|
2021
Q1 | $468K | Sell |
2,486
-4,223
| -63% | -$745K | 0.02% | 564 |
|
|
2020
Q4 | $1.1M | Sell |
6,709
-532
| -7% | -$77.8K | 0.04% | 370 |
|
|
2020
Q3 | $903K | Buy |
7,241
+3,999
| +123% | +$495K | 0.03% | 386 |
|
|
2020
Q2 | $315K | Sell |
3,242
-723
| -18% | -$75.2K | 0.01% | 607 |
|
|
2020
Q1 | $356K | Sell |
3,965
-4,360
| -52% | -$565K | 0.01% | 585 |
|
|
2019
Q4 | $1.23M | Sell |
8,325
-1,609
| -16% | -$216K | 0.04% | 399 |
|
|
2019
Q3 | $1.2M | Sell |
9,934
-14
| -0.1% | -$1.81K | 0.04% | 408 |
|
|
2019
Q2 | $1.34M | Buy |
9,948
+28
| +0.3% | +$3.54K | 0.04% | 399 |
|
|
2019
Q1 | $1.29M | Buy |
+9,920
| New | +$1.33M | 0.04% | 411 |
|
|
2017
Q3 | – | Sell |
-15,720
| Closed | -$1.37M | – | 587 |
|
|
2017
Q2 | $1.37M | Buy |
15,720
+8,700
| +124% | +$736K | 0.06% | 261 |
|
|
2017
Q1 | $625K | Buy |
+7,020
| New | +$585K | 0.03% | 415 |
|
|
2016
Q3 | – | Sell |
-34,805
| Closed | -$2.68M | – | 567 |
|
|
2016
Q2 | $2.68M | Sell |
34,805
-148,438
| -81% | -$11.7M | 0.11% | 213 |
|
|
2016
Q1 | $14.3K | Buy |
183,243
+6,347
| +4% | +$443K | 0.6% | 40 |
|
|
2015
Q4 | $12M | Sell |
176,896
-16,966
| -9% | -$1.18M | 0.5% | 77 |
|
|
2015
Q3 | $15M | Buy |
193,862
+152,882
| +373% | +$13.5M | 0.63% | 36 |
|
|
2015
Q2 | $3.08M | Hold |
40,980
| – | – | 0.12% | 221 |
|
|
2015
Q1 | $3.08M | Buy |
+40,980
| New | +$2.94M | 0.12% | 221 |
|
Other funds holding HCA
Hancock Whitney's HCA Position: Q2 2026 in Review
Hancock Whitney reduced its HCA Healthcare (HCA) stake by 40% in Q2 2026, selling an estimated $731K and leaving 2,621 shares worth $1.02M. The position accounts for 0.02% of the portfolio, ranked #439.
Hancock Whitney first reported a position in HCA in Q1 2015 and has held it in 38 quarters since. The position peaked at $15M in Q3 2015. 1,333 funds tracked by Wall St. Rank hold HCA as of Q2 2026.
- Hancock Whitney held 2,621 shares of HCA Healthcare worth $1.02M as of Q2 2026.
- Hancock Whitney sold 1,728 HCA Healthcare shares in Q2 2026, an estimated $731K.
- HCA Healthcare made up 0.02% of Hancock Whitney's portfolio in Q2 2026, its #439 holding.
- Hancock Whitney first reported a position in HCA Healthcare in Q1 2015 and has held it in 38 quarters since.
- Hancock Whitney's HCA Healthcare position peaked at $15M in Q3 2015.
- 1,333 funds tracked by Wall St. Rank held HCA Healthcare as of Q2 2026.
Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.